Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive ovarian cancer database reveals treatment trends across france

NCT ID NCT03275298

Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects information from over 13,000 women treated for ovarian cancer at 18 French cancer centers. Researchers will look at patient details, tumor types, and treatments given to see how care has evolved since 2011. The goal is to understand what treatments are used and how they affect survival, without testing any new drugs or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

13,331 people

The number who actually took part.

Started

Apr 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All consecutive females treated for an ovarian cancer in a French Comprehensive Cancer Center over the selection period.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * 18 years old female * Female who received surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) for ovarian cancer in a French Comprehensive Cancer Center. Exclusion criteria : None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Georges-François Leclerc

    Dijon, 21079, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • Institut Curie

    Paris, 75005, France

  • Institut Curie - Hôpital René Huguenin

    Saint-Cloud, 92210, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Jean Godinot

    Reims, 51056, France

  • Institut Paoli-Calmettes

    Marseille, 13273, France

  • Institut de Cancérologie de Lorraine

    Nancy, 54511, France

  • Institut de Cancérologie de l'Ouest - Paul Papin

    Angers, 49933, France

  • Institut de cancérologie de l'Ouest - René Gauducheau

    Nantes, 44805, France

  • Institut régional du Cancer Montpellier / Val d'Aurelle

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.